GEN Exclusives

More »

GEN News Highlights

More »
Jul 11, 2007

Ganymed to Use Selexis Tool to Manufacture Antibodies

  • Selexis signed a commercial license agreement with Ganymed Pharmaceuticals for use of Selexis' technology for large-scale production of Ganymed's lead antibodies.

    The deal allows Ganymed to use a high performance cell line, developed by Ganymed scientists using the Selexis SURE cell line development platform, for the clinical and commercial production of a number of products.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »